CTOs on the Move

AMPAC Fine Chemicals

www.ampacfinechemicals.com

 
AMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients (APIs) and registered intermediates for customers in the pharmaceutical industry. Our integrated facilities are located in Rancho Cordova, California, approximately 20 miles east
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Saneron CCEL Therapeutics

Saneron CCEL Therapeutics is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AmbioPharm

AmbioPharm is a Beech Island, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Letco Medical

Since 1993 Letco Medical has been committed to providing compounding pharmacies complete customer satisfaction by offering the highest quality products, customer service, technical support and the fastest delivery times in the industry. Letco is your partner in compounding. We have an extensive line of chemicals, supplies, equipment, capsules, solutions and bases to support you. Letco Medical was also the first in our industry to offer CSOS ordering for your convenience. We also offer online ordering. We pride ourselves on knowing that satisfaction of a job well done is derived through a combination of hard work, perseverance and a thoughtful approach to do our best for our customers and our company. We communicate honestly and openly to continue to build long lasting, trustworthy relationships with our customers and employees. We thank you for trusting us as partners in your compounding pharmacy. We look forward to working with you.

Genemed Synthesis

Genemed Synthesis, Inc. is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TCR2

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.